Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America Post published:November 29, 2022 Post category:Press Release
Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders Post published:November 2, 2022 Post category:Press Release
KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers Post published:October 4, 2022 Post category:Press Release
Braxia Scientific Announces Board Appointment Post published:September 22, 2022 Post category:Press Release
Braxia Scientific Announces Court Approval of Class Action Settlement in Canada Post published:September 18, 2022 Post category:Press Release
Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home Post published:September 12, 2022 Post category:Press Release
Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 Post published:September 11, 2022 Post category:Press Release
Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients Post published:August 30, 2022 Post category:Press Release
Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S. Post published:August 3, 2022 Post category:Press Release
Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results Post published:August 2, 2022 Post category:Press Release